Chromosome 7q35 and susceptibility to diabetic microvascular complications

Journal of Diabetes and its Complications

Volumn 10, Issue 2, 1996, Pages 62-67

  Patel, Ashok ^a   Hibberd, Martin L ^a   Millward, Beverley A ^a   Demaine, Andrew G ^a  

^a UNIVERSITY OF PLYMOUTH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE REDUCTASE; NITRIC OXIDE SYNTHASE; POLYOL; RESTRICTION ENDONUCLEASE; T LYMPHOCYTE RECEPTOR;

ADULT; AGED; ARTICLE; CHROMOSOME 7Q; DIABETIC ANGIOPATHY; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE PREDISPOSITION; FEMALE; GENE FREQUENCY; GENE LOCATION; GENOTYPE; HAPLOTYPE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

EID: 0029898063     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/1056-8727(95)00004-6     Document Type: Article

References (35)

1. Brownlee M: Gycosylation products as toxic mediators of diabetic complications. Annu. Rev Med 42:159-166, 1990.
2. Larkins RG, Dunlop ME: The link between hyperglycaemia and diabetic nephropathy. Diabetologia 35:499-504, 1992.
3. The DCCT Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977, 1993.
4. Dvornik D: Hyperglycemia in the pathogenesis of diabetic complications, in: Porte D (ed), Aldose Reductase Inhibition: An Approach to the Prevention of Diabetic Complications. New York, McGraw-Hill, pp. 7-151, 1987.
5. Raskin P: Risk factors for the development of diabetic complications. J Diabet Complications 8:195-200, 1994.
6. Baynes JW: Role of oxidative stress in the development of complications of diabetes. Diabetes 40:405-412, 1991.
7. Corbett JA, Tilton RG, Chang K, Hassan KS, Ido Y, Wang JI, et al.: Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes 41:552-556, 1992.
8. McVeigh GE, Brennan GM, Johnston GD, McDermott BJ, McGrath LT, Henry WR, et al.: Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 35:771-776, 1992.
9. Tomlinson DR, Moriarty RJ, Mayer JH: Prevention and reversal of defective axonal transport and motor nerve conduction velocity in rats with experimental diabetes by treatment with the aldose reductase inhibitor sorbinil. Diabetes 33:470-476, 1984.
10. Kinoshita JH, Kador P, Datiles M: Aldose reductase in diabetic cataracts. JAMA 246:257-261, 1981.
11. Goldfarb S, Simmons DA, Kern E: Amelioration of glomerular hyperfiltration in acute experimental diabetes by dietary myo-inositol and aldose reductase inhibition. Trans Assoc Am Physicians 99:67-72, 1986.
12. Masson EA, Boulton AJM: Aldose reductase inhibitors in the treatment of diabetic neuropathy: A review of the rationale and clinical evidence. Drugs 39:190-202, 1990.
13. Bohren KM, Bullock B, Wermuth B, Gabbay KH: The aldo-keto reductase superfamily. cDNAs and deduced amino acid sequences of human aldehyde and aldose reductases. J Biol Chem 264:9547-9551, 1989.
14. Chung S, LaMendola J: Cloning and sequence determination of human placental aldose reductase gene. J Biol Chem 264:14775-14777, 1989.
15. Nishimura C, Matsuura Y, Kokai Y, Akera T, Carper D, Morjana N, et al.: Cloning and expression of human aldose reductase. J Biol Chem 265:9788-9792, 1990.
16. Graham A, Heath P, Morten JEN, Markham AF: The human aldose reductase gene maps to chromosome 7q35. Hum Genet 86:509-514, 1991.
17. Graham A, Brown L, Hedge PJ, Gammack AJ, Markham AF: Structure of the human aldose reductase gene. J Biol Chem 266:6872-6877, 1991.
18. Hibberd ML, Millward BA, Wong FS, Demaine AG: T-cell receptor constant β-chain polymorphisms and susceptibility to type I diabetes. Diabetic Med 9:929-933, 1992.
19. Patel A, Ratanachaiyavong S, Millward BA, Demaine AG: Polymorphisms of the aldose reductase locus (ALR2) and susceptibility to diabetic microvascular complications. Adv Exp Mol Biol 328:325-332, 1993.
20. National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28:1039-1044, 1979.
21. Millward BA, Welsh KI, Leslie RDG, Pyke DA, Demaine AG: T-cell receptor beta chain polymorphisms are associated with insulin dependent diabetes mellitus. Clin Exp Immunol 70:152-157, 1987.
22. Gabbay KH: The sorbitol pathway and the complications of diabetes. N Engl J Med 288:831-836, 1973.
23. Winegrad AI: Does a common mechanism induce the diverse complications of diabetes? Diabetes 36:396-406, 1987.
24. Kinoshita JH, Nishimura C: The involvement of aldose reductase in diabetic complications. Diabetes Metab Rev 4:323-354, 1987.
25. Dent MT, Tebbs SE, Gonzalez AM, Ward JD, Wilson RM: Neutrophil aldose reductase activity and its association with established microvascular complications. Diabetic Med 8:4349-442, 1991.
26. Hamada Y, Kitoh R, Raskin P: Crucial role of aldose reductase activity and plasma glucose level in sorbitol accumulation in erythrocytes from diabetic patients. Diabetes 40:1233-1240, 1991.
27. Dent MT, Veves A, Tebbs SE, Gonzalez AM, Malik RA, Boulton AJM, et al.: Neutrophil aldose reductase activity as a potential marker for neuropathy and cataract in diabetes. Diabetic Med 8:911-916, 1991.
28. Hamada Y, Kitoh R, Raskin P: Association of erythrocyte aldose reductase activity with diabetic complications in type I diabetes mellitus. Diabetic Med 10:33-38, 1993.
29. Kronenberg M, Siu G, Hood LE, Shastri N: The molecular genetics of the T-cell antigen receptor. Annu Rev Immunol 5:529-591, 1986.
30. Moss PAH, Rosenberg WMC, Bell JI: The human T cell receptor in health and disease. Annu Rev Immunol 10: 71-96, 1992.
31. Bending JJ, Lobo-Yeo A, Vergani D, Viberti GC: Proteinuria and activated T-lymphocytes in diabetic nephropathy. Diabetes 37:507-511, 1988.
32. Di Mario U, Borsey DQ, Contreas G, Prowse CV, Clarke BF, Andreani D: The relationship of soluble immune complexes, insulin antibodies and insulin anti-insulin complexes to platelet and coagulation factors in type I diabetic patients with or without proliferative retinopathy. Clin Exp Immunol 65:57-65, 1986.
33. Marsden PA, Heng HHQ, Scherer SW, Stewart RJ, Hall AV, Shi X-M, Tsui L-C, Schappert KT: Structure and chromosomal localisation of the human constitutive endothelial nitric oxide synthase gene. J Biol Chem 268: 17478-17488, 1993.
34. Oyama Y, Kawasaki H, Hattori Y, Kanno M: Attenuation of endothelium-dependent relaxation in aorta from diabetic rats. Eur J Pharmacol 131:75-78.
35. Kamata K, Miyata N, Kasuya Y: Impairment of endothelium-dependent relaxation and changes in levels of cyclic GMP in aorta from streptozotocin-induced diabetic rats. Br J Pharmacol 97:614-618, 1989.